Sun Hopes Cequa’s Nano Formulation Makes Big Impact
Sun’s now-approved higher concentration, quicker-acting formulation of cyclosporine A could offer competitive advantage in dry eye versus Allergan’s Restasis, but is it enough to offset lower costs of pending generic cyclosporines?
You may also be interested in...
Cequa arrives in India, almost four years post US debut with Sun deploying what has generally been perceived as the text-book launch approach of foreign firms in the country. Scrip delves into the market dynamics in a segment where AbbVie's blockbuster Restasis is well entrenched.
Company hopes a different formulation of its intracanicular insert of cyclosporin might provide longer duration of drug in the eye and better tear production with it.
AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.